AIVF Funding: How Much Did They Raise & Key Investors

How Much Did AIVF Raise?
Funding & Key Investors

AIVF, a pioneer in the integration of artificial intelligence within reproductive medicine, has successfully secured a major strategic investment, bringing its total capital accumulation to $25M. This latest infusion of $25M underscores the growing market confidence in the company's ability to digitize and standardize complex fertility workflows. By leveraging advanced machine learning, AIVF is positioning itself as a critical infrastructure provider for global fertility clinics seeking to improve patient outcomes through data-driven precision.

The recent financing round marks a pivotal transition for the Tel Aviv-based firm, moving from initial research and development into a phase of aggressive international expansion. With the support of high-profile institutional backers, the company is well-positioned to scale its proprietary software platform, which serves as a digital backbone for modern reproductive healthcare facilities.

What is AIVF?

AIVF

Software

Healthcare Software

Founded in 2018 by Daniella Gilboa and Prof. Daniel Seidman, AIVF operates at the intersection of medical technology and reproductive health. The company provides an AI-powered software platform designed to automate and standardize the IVF process, effectively reducing the variability inherent in traditional clinical procedures. By offering fertility intelligence, AIVF enables clinics to optimize laboratory operations and enhance the accuracy of patient care protocols. Its market position is defined by its commitment to evidence-based innovation, partnering with leading global clinics to refine its algorithms and expand the reach of its reproductive medicine solutions.

How much funding has AIVF raised?

AIVF has raised a total of $25M across 1 funding round:

2022

Series A

$25M

Series A (2022): $25M with participation from Insight Partners and 166 2nd Financial Services

Key Investors in AIVF

Insight Partners

A leading global venture capital and private equity firm that invests in high-growth technology and software companies, providing deep operational support to scale portfolio businesses.

166 2nd Financial Services

A specialized financial services entity focused on strategic capital deployment and investment in emerging technology sectors.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for AIVF?

With this major enterprise-level funding, AIVF is expected to accelerate its product roadmap, focusing on the integration of new diagnostic features and the expansion of its clinical partner network. The strategic allocation of capital will likely prioritize the enhancement of its AI models to handle larger datasets, thereby increasing the predictive power of its fertility intelligence tools. As the company scales, it faces the challenge of navigating diverse regulatory landscapes in international markets, yet its strong foundation in clinical research provides a competitive moat. Future growth will likely be driven by the adoption of its platform as a standard-of-care tool, potentially leading to further strategic partnerships or future financing rounds as it cements its leadership in the digital health sector.

See full AIVF company page

See More Financial Insights